The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback